Welcome to our dedicated page for Sol Gel Tech SEC filings (Ticker: SLGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, primarily through annual reports on Form 20-F and current reports on Form 6-K. These SEC filings document the company’s activities as a dermatology-focused developer of topical drug products such as TWYNEO and EPSOLAY and pipeline candidates including SGT-610 and SGT-210.
On this page, you can review Sol-Gel’s Form 6-K submissions that furnish press releases and, in some cases, unaudited condensed consolidated financial statements for specific periods. These filings cover topics such as quarterly and semi-annual financial results, updates on the Phase 3 clinical trial of SGT-610 for Gorlin syndrome, developments in the Phase 1b study of SGT-210 in Darier disease, licensing and product purchase agreements for EPSOLAY and TWYNEO, and corporate actions like the 10-for-1 reverse share split and the transfer of the company’s listing to the Nasdaq Capital Market.
Sol-Gel’s filings also include proxy materials for annual shareholder meetings, auditor appointments, board and executive approvals and other governance matters. Certain press releases attached as exhibits to Form 6-K are expressly incorporated by reference into the company’s registration statements on Form S-8 and Form F-3, as noted in the filings. For investors analyzing SLGL, the 20-F annual report and accompanying risk factor discussions provide additional context on clinical, regulatory, financial and market risks associated with the company’s dermatology portfolio and rare disease programs.
Stock Titan’s SEC filings page for SLGL presents these documents with real-time updates from EDGAR and AI-powered summaries that highlight key points in lengthy disclosures. This helps readers quickly understand Sol-Gel’s financial position, clinical trial status, licensing arrangements and corporate actions without manually parsing every line of each 6-K or 20-F filing.
Sol-Gel Technologies Ltd. submitted a Form 6-K reporting two exhibits: a press release dated August 15, 2025 and unaudited condensed consolidated financial statements as of June 30, 2025 covering the three- and six-month periods ended June 30, 2025. The filing amends and restates the incorporation-by-reference language so that Exhibit 99.1 (except for four paragraphs immediately preceding the financial-results heading) and Exhibit 99.2 are incorporated into the company’s registration statements on Forms S-8 and F-3. The report is signed by the Chief Financial Officer, indicating the exhibits are being furnished to the SEC and made available to investors and registrants relying on the referenced registration statements.